Andrew King

Andrew King

Company: Chinook Therapeutics

Job title: Chief Scientific Officer

Seminars:

Neutralization of APRIL with BION-1301: A Targeted, Potentially Disease-Modifying Approach to IgA Nephropathy 4:00 pm

Learn how excess production of galactose-deficient IgA1 (Gd-IgA1) by IgA secreting plasma cells is considered the initiating pathogenic event (Hit 1) in IgAN Hear about PRoliferation Inducing Ligand (APRIL), a TNF-family cytokine that drives IgA class-switching, survival of IgA-secreting plasma cells and stimulates Gd-IgA1 secretion Explore how BION-1301, a novel humanized monoclonal antibody that binds…Read more

day: Day Two

Panel Discussion: Challenges & Opportunities in Drug Development for Rare Kidney Diseases 3:30 pm

Incorporating clinical outcome assessments in trials Benefits of orphan drug designation and potential accelerated approval pathways in rare renal diseases Partnering with patient advocacy groups and registries in recruiting rare kidney disease patient populationsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.